PH & T S.p.A. - search results

New Zealand - English - Medsafe (Medicines Safety Authority)

creon micro

viatris limited - pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) - modified release granules - 60.12 mg - active: pancreatin 60.12mg (3,600 ph. eur. u/amylase, 5,000 ph. eur. u/lipase and 200 ph. eur. u/protease) excipient: cetyl alcohol dimeticone hypromellose phthalate macrogol 4000 triethyl citrate - for treatment of conditions associated with pancreatic exocrine insufficiency, such as: cystic fibrosis, chronic pancreatitis, post-pancreatectomy, post-gastrointestinal bypass surgery, e.g. billroth ii, gastroenterostomy; ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

creon 10,000

viatris limited - pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.); pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. - modified release capsule - 150 mg - active: pancreatin 150mg (amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide black iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 150mg equivalent to amylase 8,000 ph eur u, lipase 10,000 ph eur u, total protease 600 ph eur u. excipient: cetyl alcohol dimeticone ferrosoferric oxide gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

New Zealand - English - Medsafe (Medicines Safety Authority)

creon 25,000

viatris limited - pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.); pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u; pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u - modified release capsule - 300 mg - active: pancreatin 300mg (amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u.) excipient: acetone dibutyl phthalate dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow liquid paraffin macrogol 4000 propyl alcohol titanium dioxide active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate titanium dioxide triethyl citrate active: pancreatin 300mg equivalent to amylase 18,000 ph eur u, lipase 25,000 ph eur u, total protease 1,000 ph eur u excipient: cetyl alcohol dimeticone gelatin hypromellose phthalate iron oxide red iron oxide yellow macrogol 4000 sodium laurilsulfate triethyl citrate - creon is indicated for the treatment of pancreatic exocrine insufficiency (pei) in paediatric and adult patients. pancreatic exocrine insufficiency is often associated with, but not limited to: · cystic fibrosis · chronic pancreatitis · post-pancreatectomy · post-gastrointestinal bypass surgery ,(e.g. billroth ii, gastroenterostomy) · ductal obstruction of the pancreas or common bile duct (e.g. from neoplasm).

United States - English - NLM (National Library of Medicine)

ph.hubby 1g sun cream intensive protection- titanium dioxide, ethylhexyl salicylate, bis-ethylhexyloxyphenol methoxyphenyl triaz

ph hubby co., ltd. - adenosine (unii: k72t3fs567) (adenosine - unii:k72t3fs567), niacinamide (unii: 25x51i8rd4) (niacinamide - unii:25x51i8rd4), titanium dioxide (unii: 15fix9v2jp) (titanium dioxide - unii:15fix9v2jp), octisalate (unii: 4x49y0596w) (octisalate - unii:4x49y0596w), bemotrizinol (unii: pwz1720cbh) (bemotrizinol - unii:pwz1720cbh) - prevention of hyperpigmentation&aging induced by uva/uvb rays all year-round. apply every morning at the end of the skincare routine of going out.

United States - English - NLM (National Library of Medicine)

ph.hubby pink bb tone up sun- titanium dioxide, ethylhexyl salicylate, bis-ethylhexyloxyphenol methoxyphenyl triazine, niacinami

United States - English - NLM (National Library of Medicine)

ph.hubby beige bb tone up sun- titanium dioxide, ethylhexyl salicylate, bis-ethylhexyloxyphenol methoxyphenyl triazine, niacinam

Kenya - English - Pharmacy and Poisons Board

softa-man solution cutaneous solution

b. braun melsungen ag 34212 melsungen - ethanol (ph.eur) 45%(w/v) propanol (ph.eur) 18%… - cutaneous solution - ethanol (ph.eur) 45%(w/v) propanol (ph.eur) 18%… - antiseptics and disinfectants: other antiseptics

Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 1000ml injection bag ahb2544

baxter healthcare pty ltd - sodium acetate, quantity: 3.68 g/l; potassium chloride, quantity: 370 mg/l; magnesium chloride hexahydrate, quantity: 300 mg/l; sodium gluconate, quantity: 5.02 g/l; sodium chloride, quantity: 5.26 g/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

Australia - English - Department of Health (Therapeutic Goods Administration)

plasma-lyte 148 (approx. ph 7.4) 500ml injection bag ahb2543

baxter healthcare pty ltd - sodium gluconate, quantity: 5.02 g/l; sodium acetate, quantity: 3.68 g/l; sodium chloride, quantity: 5.26 g/l; magnesium chloride hexahydrate, quantity: 300 mg/l; potassium chloride, quantity: 370 mg/l - injection, intravenous infusion - excipient ingredients: sodium hydroxide; water for injections - plasma-lyte 148 (approx. ph 7.4) iv infusion is indicated as a source of water and electrolytes or as an alkalinising agent.

Ireland - English - HPRA (Health Products Regulatory Authority)

plasma-lyte® 148 (ph 7.4) solution for infusion

baxter holding b.v. - sodium chloride; potassium chloride; magnesium chloride hexahydrate; sodium acetate trihydrate ; sodium gluconate - solution for infusion - 148 (ph 7.4) - solutions affecting the electrolyte balance; electrolytes